Intramuscular immunisation with chlamydial proteins induces chlamydia trachomatis specific ocular antibodies

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Badamchi Zadeh, Alexander ^a,e   McKay, Paul F ^a   Holland, Martin J ^b   Paes, Wayne ^c   Brzozowski, Andrzej ^c   Lacey, Charles ^c   Follmann, Frank ^d   Tregoning, John S ^a   Shattock, Robin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d STATENS SERUM INSTITUT   (Denmark)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; DNA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MAJOR OUTER MEMBRANE PROTEIN ANTIBODY; MIFAMURTIDE; MODIFIED VACCINIA ANKARA VACCINE; RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN PGP3; RECOMBINANT PROTEIN PMPD; UNCLASSIFIED DRUG; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL CLEARANCE; CHLAMYDIA TRACHOMATIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA IMMUNIZATION; EYE INFECTION; EYE LAVAGE; FEMALE; IMMUNIZATION; MONOTHERAPY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE; ANIMAL; BAGG ALBINO MOUSE; CHLAMYDIA INFECTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; PATHOGENICITY; TRACHOMA;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; MICE, INBRED BALB C; TRACHOMA;

EID: 84949255932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141209     Document Type: Article

References (37)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization. 2004; 82(11):844-51. Epub 2005/01/11. doi: /S0042-96862004001100009. PMID: 15640920; PubMed Central PMCID: PMC2623053.
2. WHO. Fact sheet No. 382. May 2015.
3. Kari L, Bakios LE, Goheen MM, Bess LN, Watkins HS, Southern TR, et al. Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model. PLoS neglected tropical diseases. 2013; 7(5):e2248. Epub 2013/06/06. doi: 10.1371/journal.pntd.0002248 PMID: 23738030; PubMed Central PMCID: PMC3667776.
4. Wyllie S, Ashley RH, Longbottom D, Herring AJ. The major outer membrane protein of Chlamydia psittaci functions as a porin-like ion channel. Infection and immunity. 1998; 66(11):5202-7. Epub 1998/10/ 24. PMID: 9784523; PubMed Central PMCID: PMC108649.
5. Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infection and immunity. 1981; 31(3):1161-76. Epub 1981/03/ 01. PMID: 7228399; PubMed Central PMCID: PMC351439.
6. Baehr W, Zhang YX, Joseph T, Su H, Nano FE, Everett KD, et al. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85(11):4000-4. Epub 1988/06/ 01. PMID: 2453883; PubMed Central PMCID: PMC280348.
7. Crane DD, Carlson JH, Fischer ER, Bavoil P, Hsia RC, Tan C, et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(6):1894-9. Epub 2006/02/01. doi: 10. 1073/pnas.0508983103 PMID: 16446444; PubMed Central PMCID: PMC1413641.
8. Becker E, Hegemann JH. All subtypes of the Pmp adhesin family are implicated in chlamydial virulence and show species-specific function. MicrobiologyOpen. 2014; 3(4):544-56. doi: 10.1002/mbo3.186 PMID: 24985494
9. Kari L, Southern TR, Downey CJ, Watkins HS, Randall LB, Taylor LD, et al. Chlamydia trachomatis Polymorphic Membrane Protein D is a Virulence Factor Involved in Early Host Cell Interactions. Infection and immunity. 2014. Epub 2014/04/16. doi: 10.1128/IAI.01686-14 PMID: 24733093.
10. Hu VH, Holland MJ, Burton MJ. Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl Trop Dis. 2013; 7(2):e2020. doi: 10.1371/journal.pntd.0002020 PMID: 23457650; PubMed Central PMCID: PMCPMC3573101.
11. Li Z, Chen D, Zhong Y, Wang S, Zhong G. The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infection and immunity. 2008; 76(8):3415-28. Epub 2008/ 05/14. doi: 10.1128/IAI.01377-07 PMID: 18474640; PubMed Central PMCID: PMC2493211.
12. Barouch DH, Pau MG, Custers JHHV, Koudstaal W, Kostense S, Havenga MJE, et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity. The Journal of Immunology. 2004; 172(10):6290-7. doi: 10.4049/jimmunol.172.10.6290 PMID: 15128818
13. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl):S45-S53. PMID: 15812489
14. Buffa V, Klein K, Fischetti L, Shattock RJ. Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice. PloS one. 2012; 7(12):e50529. doi: 10.1371/journal.pone. 0050529 PMID: 23272062
15. McKay PF, Cope AV, Mann JF, Joseph S, Esteban M, Tatoud R, et al. Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen. PloS one. 2014; 9(1):e84707. doi: 10.1371/journal.pone.0084707 PMID: 24465426; PubMed Central PMCID: PMC3900398.
16. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. Journal of virology. 1999; 73(5):3723-32. Epub 1999/04/10. PMID: 10196265; PubMed Central PMCID: PMC104148.
17. Fu YH, He JS, Zheng XX, Wang XB, Xie C, Shi CX, et al. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Biochemical and biophysical research communications. 2010; 391(1):857-61. Epub 2009/12/01. doi: 10.1016/j. bbrc.2009.11.152 PMID: 19945423.
18. Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine. 2011; 29(18):3456-64. Epub 2011/03/08. doi: 10.1016/j.vaccine.2011.02.057 PMID: 21376796; PubMed Central PMCID: PMC3084512.
19. Campos M, Pal S, O'Brien TP, Taylor HR, Prendergast RA, Whittum-Hudson JA. A chlamydial major outer membrane protein extract as a trachoma vaccine candidate. Investigative ophthalmology & visual science. 1995; 36(8):1477-91. Epub 1995/07/01. PMID: 7601629.
20. Hessel T, Dhital SP, Plank R, Dean D. Immune response to chlamydial 60-kilodalton heat shock protein in tears from Nepali trachoma patients. Infection and immunity. 2001; 69(8):4996-5000. Epub 2001/07/12 doi: 10.1128/IAI.69.8.4996-5000.2001 PMID: 11447178; PubMed Central PMCID: PMC98592.
21. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecologic oncology. 2008; 110(3 Suppl 1):S1-10. Epub 2008/07/26. doi: 10.1016/j.ygyno.2008.05.036 PMID: 18653222.
22. Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. Journal of immunology. 2012; 188(7):3088-98. Epub 2012/02/22. doi: 10.4049/jimmunol.1101764 PMID: 22351935.
23. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, et al. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140. PloS one. 2012; 7(7):e41144. doi: 10.1371/journal.pone. 0041144 PMID: 22829921
24. Van Roey GA, Arias MA, Tregoning JS, Rowe G, Shattock RJ. Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. European journal of immunology. 2012; 42(2):353-63. doi: 10.1002/eji.201141787 PMID: 22057556; PubMed Central PMCID: PMC3378695.
25. Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, et al. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. Journal of virology. 2014; 88(10):5502-10. Epub 2014/03/07. doi: 10.1128/ JVI.03574-13 PMID: 24599994; PubMed Central PMCID: PMC4019094.
26. Veazey RS, Siddiqui A, Klein K, Buffa V, Fischetti L, Doyle-Meyers L, et al. Evaluation of mucosal adjuvants and immunisation routes for the induction of systemic and mucosal humoral immune responses in macaques. Human Vaccines and Immunotherapeutics. 2015;In Press.
27. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012; 491(7424):463-7. doi: 10.1038/nature11522 PMID: 23075848
28. Tregoning JS, Buffa V, Oszmiana A, Klein K, Walters AA, Shattock RJ. A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PloS one. 2013; 8 (11):e80559. doi: 10.1371/journal.pone.0080559 PMID: 24260419; PubMed Central PMCID: PMC3834027.
29. Karagouni EE, Hadjipetrou-Kourounakis L. Regulation of isotype immunoglobulin production by adjuvants in vivo. Scandinavian journal of immunology. 1990; 31(6):745-54. Epub 1990/06/01. PMID: 1694039.
30. Avramidis N, Victoratos P, Yiangou M, Hadjipetrou-Kourounakis L. Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice. Veterinary microbiology. 2002; 88(4):325-38. Epub 2002/09/11. PMID: 12220808.
31. Bailey RL, Kajbaf M, Whittle HC, Ward ME, Mabey DC. The influence of local antichlamydial antibody on the acquisition and persistence of human ocular chlamydial infection: IgG antibodies are not protective. Epidemiology and infection. 1993; 111(2):315-24. Epub 1993/10/01. PMID: 8405158; PubMed Central PMCID: PMC2271382.
32. Kari L, Whitmire WM, Olivares-Zavaleta N, Goheen MM, Taylor LD, Carlson JH, et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. Journal of Experimental Medicine. 2011; 208(11):2217-23. doi: 10.1084/jem.20111266 PMID: 21987657
33. Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. J Infect Dis. 2015. doi: 10.1093/ infdis/jiv137 PMID: 25748320.
34. Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM, et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. Journal of immunology. 2009; 182(12):8063-70. doi: 10. 4049/jimmunol.0804375 PMID: 19494332; PubMed Central PMCID: PMC2692073.
35. Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, et al. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015; 348 (6241):aaa8205-aaa. doi: 10.1126/science.aaa8205 PMID: 26089520
36. Whittum-Hudson JA, O'Brien TP, Prendergast RA. Murine model of ocular infection by a human biovar of Chlamydia trachomatis. Invest Ophthalmol Vis Sci. 1995; 36(10):1976-87. PMID: 7657540.
37. Wilson DP, Bowlin AK, Bavoil PM, Rank RG. Ocular pathologic response elicited by Chlamydia organisms and the predictive value of quantitative modeling. J Infect Dis. 2009; 199(12):1780-9. doi: 10. 1086/599093 PMID: 19419335.